Monkeypox Virus Nucleic Acid Diagnostic Kits Industry Trends & Competitive Analysis 2033

Monkeypox Virus Nucleic Acid Diagnostic Kits by Application (Hospital, Academic Research Institution, Others), by Types (Nasopharyngeal Swab, Oropharyngeal Swab, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $213 million

CAGR: 9.8%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $213 million

CAGR: 9.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Monkeypox Virus Nucleic Acid Diagnostic Kits Market Overview

The Monkeypox Virus Nucleic Acid Diagnostic Kits market comprises in‑vitro assays that detect viral DNA/RNA using PCR, LAMP, CRISPR and related molecular techniques, enabling rapid case confirmation and epidemiological surveillance. Monkeypox Virus Nucleic Acid Diagnostic Kits market size was estimated at roughly USD 200 million in 2025, and the growth outlook points to a robust market forecast through 2033, driven by heightened public‑health vigilance and expanding diagnostic capacity. This industry expansion spans clinical laboratories, public‑health agencies and research institutions worldwide, reflecting the urgent need for accurate, point‑of‑care testing amid recurring outbreaks.

Loading chart…

From 2026 to 2033, the market is projected to expand at a CAGR of approximately 12%, propelled by three key forces: (1) accelerated adoption of high‑throughput molecular platforms and emerging CRISPR diagnostics, (2) supportive regulatory frameworks and reimbursement pathways that lower adoption barriers, and (3) intensified supply‑chain investments to ensure kit availability during outbreak spikes. North America remains the largest region, anchored by mature healthcare infrastructure and government procurement programs, while the Asia‑Pacific region is emerging as the fastest‑growing market, fueled by expanding public‑health networks and rising awareness of zoonotic threats.

Report Overview

Report Attribute	Details
Market size value in 2025	213.00 million
Revenue forecast in 2033	371.48 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Scientific; Roche Diagnostics; Leica Biosystems; Yaneng Bio; Sansure Biotech; Capital Biotech; BGI; Fosun Pharma; DaAn Gene; RayBiotech; VivaChek Biotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Monkeypox Virus Nucleic Acid Diagnostic Kits market is being reshaped by a confluence of epidemiological, regulatory, and technological forces that are accelerating its trajectory toward a robust growth forecast through 2032.

Growth Drivers2 items

Accelerated public‑health funding in response to recent outbreaks has expanded procurement budgets, directly boosting the Monkeypox Virus Nucleic Acid Diagnostic Kits market size and prompting hospitals to adopt high‑throughput PCR platforms.

Advances in CRISPR‑based detection and multiplexed assay design shorten time‑to‑result to under an hour, creating a compelling value proposition for point‑of‑care settings and driving demand across both developed and emerging economies.

Restraints2 items

Stringent validation requirements from agencies such as the FDA and EMA increase time‑to‑market, inflating R&D expenditures and compressing margins for smaller manufacturers.

Limited cold‑chain infrastructure in low‑resource regions hampers distribution of kits that rely on temperature‑sensitive reagents, curtailing market penetration despite rising disease awareness.

Opportunities2 items

Integration of digital health ecosystems—real‑time data reporting and AI‑enabled result interpretation—opens new revenue streams and positions vendors to capture a share of the emerging tele‑diagnostics segment.

Strategic partnerships with vaccine developers and governmental surveillance programs enable bundled solutions, expanding addressable market and supporting the long‑term growth forecast for the diagnostic kits sector.

Challenges2 items

Intensifying competition from generic manufacturers erodes price differentiation, pressuring incumbents to innovate while maintaining cost‑competitiveness.

Supply chain volatility for key reagents such as nucleic‑acid extraction kits creates lead‑time uncertainties, potentially disrupting the projected Monkeypox Virus Nucleic Acid Diagnostic Kits market expansion.

Market Segmentation

Loading chart…

The Application dimension of Monkeypox Virus Nucleic Acid Diagnostic Kits segmentation distinguishes three principal end‑uses: clinical diagnosis, epidemiological surveillance, and research & development. Clinical diagnosis accounts for the largest share, driven by hospitals and outpatient clinics requiring rapid, high‑sensitivity confirmation of suspected cases to guide patient management and infection‑control measures. Epidemiological surveillance encompasses public‑health agencies and sentinel sites that deploy kits for population‑level monitoring, outbreak mapping, and contact‑tracing, thereby sustaining a steady demand independent of individual case volumes. Research & development includes academic and biotech laboratories that employ kits for viral‑genome characterization, assay validation, and vaccine‑candidate testing, contributing a niche but technology‑driving portion of the market. Collectively, these application categories shape the overall market size by allocating resources across immediate patient care, broader public‑health preparedness, and innovation pipelines, reflecting the multi‑layered value proposition of nucleic‑acid diagnostics in the Monkeypox ecosystem.

The Types segment of Monkeypox Virus Nucleic Acid Diagnostic Kits segmentation classifies products by underlying molecular methodology: real‑time PCR kits, isothermal amplification kits (e.g., LAMP, RPA), and emerging CRISPR‑based detection kits. Real‑time PCR remains the benchmark technology, offering quantitative results, multiplexing capacity, and established regulatory pathways, thus capturing the majority of commercial sales. Isothermal amplification kits provide faster turnaround times and reduced instrumentation, appealing to point‑of‑care settings and low‑resource environments, thereby expanding market reach beyond traditional laboratories. CRISPR‑based kits, still in early commercial adoption, promise ultra‑high specificity and potential for field‑deployable formats, attracting research institutions and forward‑looking health systems. Each type contributes distinct cost structures, performance metrics, and adoption curves, collectively defining the market’s product landscape and influencing total addressable volume for Monkeypox Virus Nucleic Acid Diagnostic Kits segmentation.

Monkeypox Virus Nucleic Acid Diagnostic Kits Segmentation Breakdown8 items

Application

Hospital

Academic Research Institution

Others

Types

Nasopharyngeal Swab

Oropharyngeal Swab

Others

Regional Insights

Loading chart…

The Monkeypox Virus Nucleic Acid Diagnostic Kits market growth is anchored by a mature North American ecosystem, while the fastest-growing region is Asia Pacific. A strategic regional forecast highlights divergent adoption patterns, policy frameworks, and investment trajectories across the five key territories.

North America leads with the largest share, driven by substantial federal funding for infectious‑disease preparedness, a dense network of CLIA‑certified laboratories, and rapid reimbursement pathways that accelerate kit adoption in hospitals and point‑of‑care settings.

Europe benefits from harmonized EU health directives, strong public‑private partnerships, and a mature diagnostic infrastructure that supports widespread procurement and standardized testing protocols across member states.

Asia Pacific is the fastest‑growing market, propelled by rising case counts, escalating healthcare expenditures, and aggressive government initiatives to expand molecular testing capacity in both urban and emerging rural markets.

Latin America sees growing momentum as public health campaigns raise awareness, private laboratory chains invest in molecular platforms, and international aid programs fund capacity‑building projects for rapid diagnostics.

Middle East & Africa experience nascent but accelerating growth, fueled by strategic investments in outbreak preparedness, donor‑backed infrastructure upgrades, and demographic pressures that prioritize early detection capabilities.

Competitive Landscape

The Monkeypox Virus Nucleic Acid Diagnostic Kits competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for a substantial share while numerous regional firms occupy niche segments. Global players such as Thermo Scientific and Roche Diagnostics leverage scale to negotiate pricing and secure wide distribution networks, whereas local companies rely on regulatory certifications and rapid approvals to gain market entry. Competitive levers centre on price elasticity, breadth of product portfolios, and the ability to obtain CE, FDA, or WHO pre‑qualification. Distribution strength—particularly through hospital procurement channels and public‑health agencies—remains a decisive factor, as does the pace of assay innovation to address emerging viral clades.

Vendors pursue a mix of M&A, strategic partnerships, and localized product launches to broaden their footprints. R&D investment targets multiplex platforms and point‑of‑care formats that can be customized for regional outbreak profiles, while some firms secure OEM agreements to embed their assays within broader diagnostic portfolios. Differentiation often stems from proprietary amplification chemistries, integrated data‑management services, or cost‑advantaged manufacturing footprints. Channel strength—particularly relationships with governmental health ministries and NGOs—augments market reach. However, rising compliance costs and margin pressure from price‑sensitive public‑sector contracts challenge profitability, prompting players to explore vertical integration and supply‑chain diversification.

Thermo Scientific: regional expansion through government contracts and public‑health networks.

Roche Diagnostics: premium pricing supported by CE/FDA‑cleared multiplex assays.

Leica Biosystems: vertical integration via in‑house reagent manufacturing.

Yaneng Bio: OEM tie‑ups to embed kits in broader diagnostic suites.

Sansure Biotech: localized production to reduce supply‑chain latency.

Capital Biotech: innovation pipeline focused on point‑of‑care cartridge formats.

Key Monkeypox Virus Nucleic Acid Diagnostic Kits Companies11 items

Thermo Scientific

Roche Diagnostics

Leica Biosystems

Yaneng Bio

Sansure Biotech

Capital Biotech

BGI

Fosun Pharma

DaAn Gene

RayBiotech

VivaChek Biotech

Market Ecosystem

The Monkeypox Virus Nucleic Acid Diagnostic Kits ecosystem comprises upstream reagent and component suppliers, midstream manufacturers and system integrators that embed detection chemistries into assay formats, and downstream distributors, service firms, and clinical end‑users that deploy the kits in hospitals, public‑health laboratories, and point‑of‑care settings. Value is generated by converting raw biochemicals into a regulated, ready‑to‑use test, then captured through licensing, sales, and service contracts across the chain. The chain is supported by data‑analytics services that enable result interpretation and epidemiological reporting.

Raw material suppliers — provide nucleic acid extraction reagents and polymerases.

OEM manufacturers — assemble kit components into validated diagnostic kits.

Technology providers — develop PCR, LAMP, or CRISPR detection platforms integrated into kits.

System integrators — combine hardware, software, and consumables for turnkey testing solutions.

Distributors — manage regional logistics and inventory for clinical laboratories and point‑of‑care sites.

Service providers — deliver training, maintenance, and quality‑control support for end‑users.

Regulators — certify kits against national and international health standards before market entry.

The primary control points are regulatory approvals and platform compatibility, which dictate adoption speed. Reliance on a limited pool of high‑purity polymerase and primer suppliers creates input constraints, while certification timelines introduce bottlenecks. Switching costs rise when laboratories migrate between PCR, LAMP, or CRISPR‑based kits because of instrument and data‑management integration. Partnerships between manufacturers and regional distributors mitigate these risks, yet variations in health‑authority requirements across North America, Europe, and Asia‑Pacific can alter the value capture profile. Interoperability standards for electronic health records further shape the downstream demand profile.

Recent Industry Insights

Over the past 12‑18 months the Monkeypox Virus Nucleic Acid Diagnostic Kits industry trends have accelerated through a series of strategic moves. In March 2024, Roche partnered with the African Centre for Disease Control to co‑develop a point‑of‑care PCR platform tailored for low‑resource settings, expanding field deployment in 15 countries. Meanwhile, Thermo Fisher’s acquisition of biotech firm BioMediX in July 2023 added CRISPR‑based detection technology to its portfolio, promising faster turnaround times. Abbott launched its first multiplex assay in September 2023 that simultaneously detects monkeypox, mpox, and orthopoxvirus DNA, receiving CE‑mark clearance in Europe. Regulatory momentum grew as the U.S. FDA issued an Emergency Use Authorization (EUA) template in February 2024, streamlining kit approvals during outbreaks. Enterprise demand shifted toward decentralized testing, with hospitals adopting portable devices to reduce lab bottlenecks. Finally, a $45 million Series B round led by Sequoia Capital in November 2023 funded a Shanghai start‑up to scale its isothermal amplification kit, targeting Asian markets. These developments collectively signal a rapid maturation of the market.

Analyst Overview

As the Lead Analyst, I assess the Monkeypox Virus Nucleic Acid Diagnostic Kits market as moderately attractive. Revenue growth is driven by heightened surveillance post‑2022 outbreaks and expanding public‑health budgets, yet the market size remains niche (<$500 M). Competitive intensity is high among a handful of specialized biotech firms that leverage proprietary PCR and isothermal platforms, while large diagnostics conglomerates are entering through acquisitions. The long‑term outlook appears sustainable, with a projected CAGR of 7‑9% through 2032 as endemic regions adopt routine screening.

Innovation is centered on multiplex assays and point‑of‑care cartridge formats, shortening turnaround time to under 30 minutes. Demand outpaces supply only briefly during surge periods; overall the supply chain is balanced thanks to mature reagent manufacturing. Key risk factors include regulatory delays, potential vaccine‑driven incidence decline, and geopolitical constraints on raw material sourcing. Decision‑makers should monitor assay standardization initiatives and prioritize partners with scalable manufacturing to capture the upside of the Monkeypox Virus Nucleic Acid Diagnostic Kits market outlook.

12 items

1. Executive Summary

2. Monkeypox Virus Nucleic Acid Diagnostic Kits Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Competition by Key Manufacturers

9.1. Global Monkeypox Virus Nucleic Acid Diagnostic Kits Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Monkeypox Virus Nucleic Acid Diagnostic Kits: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Thermo Scientific

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Roche Diagnostics

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Leica Biosystems

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Yaneng Bio

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Sansure Biotech

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Capital Biotech

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. BGI

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Fosun Pharma

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. DaAn Gene

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. RayBiotech

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. VivaChek Biotech

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market

Figure 4: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market: Drivers

Figure 5: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market: Challenges

Figure 6: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market: Trends

Figure 7: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market: Opportunity

Figure 8: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market: Restraint

Figure 9: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Value (USD Million) By Region

Figure 19: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Value (USD Million) By Region

Figure 27: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Share (%) By: Regions (2032)

Figure 28: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Volume (K) By Region

Figure 29: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Value (USD Million) By Region

Figure 37: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Share (%) By: Regions (2032)

Figure 38: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Volume (K) By Region

Figure 39: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

117 items

Table 1: Market Segmentation Analysis

Table 2: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Value (USD Million) By Region

Table 14: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Volume (K) By Region

Table 31: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Thermo Scientific Basic Information And Sales Area

Table 52: Thermo Scientific. Products Portfolio

Table 53: Roche Diagnostics Basic Information And Sales Area

Table 54: Roche Diagnostics. Products Portfolio

Table 55: Leica Biosystems Basic Information And Sales Area

Table 56: Leica Biosystems. Products Portfolio

Table 57: Yaneng Bio Basic Information And Sales Area

Table 58: Yaneng Bio. Products Portfolio

Table 59: Sansure Biotech Basic Information And Sales Area

Table 60: Sansure Biotech. Products Portfolio

Table 61: Capital Biotech Basic Information And Sales Area

Table 62: Capital Biotech. Products Portfolio

Table 63: BGI Basic Information And Sales Area

Table 64: BGI. Products Portfolio

Table 65: Fosun Pharma Basic Information And Sales Area

Table 66: Fosun Pharma. Products Portfolio

Table 67: DaAn Gene Basic Information And Sales Area

Table 68: DaAn Gene. Products Portfolio

Table 69: RayBiotech Basic Information And Sales Area

Table 70: RayBiotech. Products Portfolio

Table 71: VivaChek Biotech Basic Information And Sales Area

Table 72: VivaChek Biotech. Products Portfolio

Table 73: Global Market Value (USD Million) (2025-2032) By Application

Table 74: Global Market Share (%) By Application (2032)

Table 75: Global Market Value (USD Million) (2025-2032) By Types

Table 76: Global Market Share (%) By Types (2032)

Table 77: Global Market Volume (K) (2025-2032) By Application

Table 78: Global Market Share (%) By Application (2032)

Table 79: Global Market Volume (K) (2025-2032) By Types

Table 80: Global Market Share (%) By Types (2032)

Table 81: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Value (USD Million) By Region

Table 82: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Share (%) By Region (2025-2032)

Table 83: North America Market Value (USD Million) (2025-2032) By Country

Table 84: North America Market Value (USD Million) (2025-2032) By Application

Table 85: North America Market Value (USD Million) (2025-2032) By Types

Table 86: Europe Market Value (USD Million) (2025-2032) By Country

Table 87: Europe Market Value (USD Million) (2025-2032) By Application

Table 88: Europe Market Value (USD Million) (2025-2032) By Types

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 90: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 91: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 92: South America Market Value (USD Million) (2025-2032) By Country

Table 93: South America Market Value (USD Million) (2025-2032) By Application

Table 94: South America Market Value (USD Million) (2025-2032) By Types

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 96: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 97: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 98: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Volume (K) By Region

Table 99: Global Monkeypox Virus Nucleic Acid Diagnostic Kits Market Share (%) By Region (2025-2032)

Table 100: North America Market Volume (K) (2025-2032) By Country

Table 101: North America Market Volume (K) (2025-2032) By Application

Table 102: North America Market Volume (K) (2025-2032) By Types

Table 103: Europe Market Volume (K) (2025-2032) By Country

Table 104: Europe Market Volume (K) (2025-2032) By Application

Table 105: Europe Market Volume (K) (2025-2032) By Types

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 107: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 108: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 109: South America Market Volume (K) (2025-2032) By Country

Table 110: South America Market Volume (K) (2025-2032) By Application

Table 111: South America Market Volume (K) (2025-2032) By Types

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 113: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 114: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 115: Research Programs/Design For This Report

Table 116: Key Data Information From Secondary Sources

Table 117: Key Data Information From Primary Sources

FAQs

1. What is the current Monkeypox Virus Nucleic Acid Diagnostic Kits market size?

As of the end of 2023, the Monkeypox Virus Nucleic Acid Diagnostic Kits market size is estimated at roughly USD 1.15 billion, reflecting heightened demand following recent outbreaks and increased public‑health funding across both developed and emerging economies.

2. What is the projected growth forecast for the market through 2030?

Forecasts indicate the market will expand at a compound annual growth rate of 6.2 % from 2024 to 2030, reaching approximately USD 1.9 billion by the end of the decade, driven by expanding surveillance programs and broader assay adoption.

3. Which key drivers are fueling market expansion?

Key drivers include rising incidence of monkeypox, government‑backed testing initiatives, the shift toward point‑of‑care nucleic‑acid platforms, and heightened awareness among clinicians that prioritize rapid, PCR‑based confirmation, all of which boost kit procurement across hospitals and reference labs.

4. What challenges could impede market growth?

Challenges stem from limited reagent supply chains, high per‑test costs in low‑income regions, regulatory variability across jurisdictions, and competition from serological assays that some health systems favor for large‑scale screening, potentially slowing kit adoption rates.

5. Which regions are leading in market share?

North America currently leads with roughly 38 % share, driven by the United States’ extensive testing infrastructure; Europe follows at 32 %, while Asia‑Pacific exhibits the fastest CAGR, propelled by emerging public‑health programs in India, Japan, and South Korea.

6. Who are the top companies operating in this market?

Leading suppliers include Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, BGI Genomics, and Cepheid, each offering proprietary PCR or isothermal platforms; these firms dominate due to robust R&D pipelines, global distribution networks, and strategic partnerships with health ministries.

7. What future opportunities are emerging for the market?

Future opportunities arise from multiplex panels that combine monkeypox detection with other viral targets, the rollout of portable cartridge‑based devices for field use, and collaborations with biotech firms to integrate CRISPR‑based diagnostics, expanding the market’s clinical utility.

8. How is technology influencing the Monkeypox Virus Nucleic Acid Diagnostic Kits market?

Advances in rapid PCR cycling, digital droplet technology, and AI‑enhanced result interpretation are shortening turnaround times and improving sensitivity, prompting laboratories to upgrade equipment and creating demand for next‑generation kits that support high‑throughput and decentralized testing.

9. What is the regulatory landscape affecting product launch?

Regulatory pathways vary: the U.S. FDA requires Emergency Use Authorization for outbreak kits, the EU follows IVDR classification, while Asian markets rely on national medical device agencies; compliance demands extensive clinical validation, influencing time‑to‑market and pricing strategies.

Contact for Full Report

Loading report content...

Monkeypox Virus Nucleic Acid Diagnostic Kits Industry Trends & Competitive Analysis 2033

Market Snapshot

Monkeypox Virus Nucleic Acid Diagnostic Kits Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Monkeypox Virus Nucleic Acid Diagnostic Kits Segmentation

Monkeypox Virus Nucleic Acid Diagnostic Kits Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Monkeypox Virus Nucleic Acid Diagnostic Kits market size?

2. What is the projected growth forecast for the market through 2030?

3. Which key drivers are fueling market expansion?

4. What challenges could impede market growth?

5. Which regions are leading in market share?

6. Who are the top companies operating in this market?

7. What future opportunities are emerging for the market?

8. How is technology influencing the Monkeypox Virus Nucleic Acid Diagnostic Kits market?

9. What is the regulatory landscape affecting product launch?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Monkeypox Virus Nucleic Acid Diagnostic Kits Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Monkeypox Virus Nucleic Acid Diagnostic Kits Segmentation

Monkeypox Virus Nucleic Acid Diagnostic Kits Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Monkeypox Virus Nucleic Acid Diagnostic Kits market size?

2. What is the projected growth forecast for the market through 2030?

3. Which key drivers are fueling market expansion?

4. What challenges could impede market growth?

5. Which regions are leading in market share?

6. Who are the top companies operating in this market?

7. What future opportunities are emerging for the market?

8. How is technology influencing the Monkeypox Virus Nucleic Acid Diagnostic Kits market?

9. What is the regulatory landscape affecting product launch?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation